Pfizer announced Thursday that its vaccine candidate for respiratory syncytial virus was 85.7% effective in preventing lower respiratory tract illness in older adults.
Pfizer announced Thursday that its vaccine candidate for respiratory syncytial virus was 85.7% effective in preventing lower respiratory tract illness in older adults.
